Le Lézard
Classified in: Health
Subject: FDA

Rapid Medical Announces FDA Approval of Novel Temporary Aneurysm Embolization Assist Device


YOKNEAM, Israel, May 7, 2019 /PRNewswire/ -- Rapid Medical, a company focused on the development of next generation neurovascular devices, today announced that its Comaneci device received FDA clearance as a Temporary Coil Embolization Assist Device. The Comaneci is the first and only device in a new category of temporary coil embolization assist devices. 

The Comaneci is the first-ever adjustable, fully-visible aneurysm remodeling device. It acts as a temporary bridge used to aid in the coiling processes while minimizing the risk of coil protrusion or prolapse. Once the coiling procedure is completed the device is removed from the parent artery. It is the only temporary coiling assist device that does not require parent vessel occlusion during coiling procedure or the need for long-term antiplatelet medication in case of permanent stenting. Until now the Comaneci have been successfully used in about 3,000 procedures outside the US.

"I am excited about having the Comaneci in the US. It should be a valuable alternative for ruptured and unruptured wide neck aneurysms, typically requiring balloon assistance for coil embolization, since it provides temporary protection of the parent artery during aneurysm coiling without arresting flow," said Peter Kim Nelson, MD, Professor in the Departments of Radiology and Neurosurgery in the New York University School of Medicine and Chief of the Bernard and Irene Schwartz Interventional Neuroradiology Section within the NYU Langone Health system.

"We are extremely pleased by FDA's clearance of the Comaneci device, which will be our first device available in the US.  We want to thank the FDA team for their efforts during the review process to bring it to a successful completion," said Dr. Orit Yaniv, VP of Regulatory Affairs at Rapid Medical.

About Rapid Medical

Rapid Medical is developing game-changing devices for endovascular treatments. Rapid Medical is the maker of TIGERTRIEVER, the first-ever controllable, fully visible stentriever that is designed to treat ischemic stroke patients, and, COMANECI, the first-ever controllable aneurysm neck-bridging device. TIGERTRIEVER and COMANECI are CE marked for use in Europe. More information is available at www.rapid-medical.com.

Contact:
Ronen Eckhouse
+972-72-2503331  
ronen@rapid-medical.com

 


These press releases may also interest you

at 16:10
The report on the global image-guided therapy systems market provides qualitative and quantitative analysis for the period from 2016 to 2024. Read the full report: https://www.reportlinker.com/p05751700/?utm_source=PRN The report predicts the global...

at 15:45
The "Stem Cell Manufacturing Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The Stem Cell Manufacturing market is projected to grow with a CAGR of nearly 3.3% over the forecast...

at 15:30
Experts in pediatric heart disease from across the country shared the latest findings from their research at a large national conference hosted by the Cardiac Center at Children's Hospital of Philadelphia (CHOP). The 23rd Annual Update on Pediatric...

at 15:30
February 18, 2020 The itinerary of events includes: Trenton, Ontario 10:00a.m. EST:  Minister Hajdu will meet with staff from the Public Health Agency of Canada, Health Canada, Public Safety Canada, and the Ontario Emergency Medical Assistance Team,...

at 15:19
Therapists who treat traumatized patients are familiar with the challenges they face. Often they struggle with ongoing symptoms that prevent them from engaging in many therapy modalities. Other modalities are re-traumatizing or distressing to them....

at 15:00
The "Veterinary Pharmaceuticals Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering. The global veterinary pharmaceuticals market was valued at about $12.8 billion in 2018 and is expected to grow to $21.32 billion at...



News published on 7 may 2019 at 04:00 and distributed by: